Browse by Industry
Filter News
Found 113,692 articles
-
LAG-3 is a priority focus in cancer immunotherapy because its inhibition has the potential to make PD-1 inhibitors work in more patients.
-
In-line with XVIVO’s Dedication to the US Market, Fredrik Dalborg is Appointed Managing Director North America
12/8/2021
To successfully execute on XVIVO's strategy, Fredrik Dalborg has been appointed Managing Director North America and will become a member of the XVIVO executive management team.
-
Pixium Vision gaining confidence in execution timeline of the PRIMAvera pivotal trial following first patient implantation in the UK
12/8/2021
Paris, France,December8, 2021 – 07.00 CET– Pixium Vision SA, a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces the successful implantation of the first patient in the UK in the PRIMAvera pivotal trial in atrophic dry age-related macular degeneration.
-
Valneva Signs Advance Purchase Agreement with Bahrain for Inactivated COVID-19 Vaccine VLA2001
12/8/2021
ValnevaSE, a specialty vaccine company, announced the signing of an advance purchase agreement with the Kingdom of Bahrain for the supply of one million doses of the Company’s inactivated COVID-19 vaccine candidate VLA2001.
-
NeuroSigma Announces a $5 Million Equity Investment by KT Corporation
12/8/2021
NeuroSigma, Inc., a bioelectronic medical device company, announced that KT Corporation has made a $5 million equity investment in NeuroSigma.
-
Iktos Announces Deployment of Their AI for Drug Design Software Makya™ by Jiangsu Hengrui Pharmaceuticals Co., Ltd.
12/8/2021
Iktos, a company specialized in Artificial Intelligence for new drug design announced recent collaboration agreement in AI for new drug design with Jiangsu Hengrui Pharmaceuticals Co., Ltd., a leading global pharmaceutical company based in China with a focus on research, development, manufacturing, and commercialization of innovative and high-quality healthcare products.
-
InDex Pharmaceuticals enrols first patient in the PK study with cobitolimod
12/8/2021
InDex Pharmaceuticals Holding AB announced that the first patient has been enrolled in the clinical pharmacokinetic study with cobitolimod.
-
MRM Health Announces First Patient Dosed with Next Generation Live Microbiome Consortia Therapeutic MH002 in Phase 1b/2a Study in Patients with Ulcerative Colitis
12/8/2021
MRM Health, a clinical-stage biopharmaceutical company developing next-generation live microbiome consortia therapeutics, announced that the first patient received MH002 in a phase 1b/2a multi-center clinical trial in mild-to-moderate Ulcerative Colitis.
-
BioInvent has Submitted a CTA for a Phase 1/2a trial of BI-1607, a Novel anti-FcyRIIB Antibody for the Treatment of Patients with Solid Tumors
12/8/2021
BioInvent International AB, a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, announces it has submitted a Clinical Trial Application for the novel, fully human FcyRIIB-blocking antibody, BI-1607.
-
Promore Pharma Granted US Patent Regarding Treatment Of Chronic Wounds
12/8/2021
Promore Pharma AB, a Swedish biopharmaceutical developer of therapeutic peptides, have announced that the company has received a granted patent in the US for the use of the candidate drug ropocamptide for the treatment of chronic wounds.
-
Adicet Bio, Inc. Announces Pricing of Public Offering of Common Stock - Dec 08, 2021
12/8/2021
Adicet Bio, Inc., a biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer and other diseases, announced the pricing of an underwritten public offering of 6,250,000 shares of its common stock at a public offering price of $14.00 per share.
-
Continued strong Cresemba® (isavuconazole) sales by Pfizer trigger USD 10 million sales milestone payment to Basilea
12/8/2021
Basilea Pharmaceutica Ltd., a commercial-stage biopharmaceutical company committed to meeting the needs of patients with infectious diseases and cancer, announced that sales of the antifungal Cresemba® by its partner Pfizer in Europe, Russia and Israel exceeded the threshold triggering a milestone payment to Basilea of USD 10 million.
-
Biopharmaceutical firm Alvotech Holdings announced merger plans with Oaktree Acquisition Corp. in a deal that will create a combined entity worth around $2.25 billion.
-
The news comes just three weeks after Merck paused its Phase II IMAGINE-DR trial, which was studying a combination of islatravir with MK-8507.
-
vTv Therapeutics said that the funds it saves through this process will allow it to focus on the Phase III development of TP399 and the company's future growth.
-
Ionis will manufacture and supply the drug for ongoing trials and process qualifications, while AstraZeneca will handle the commercial supply of eplontersen.
-
The WHO's latest decision is based on advice from an independent panel of experts who evaluated data from 16 randomized controlled studies.
-
Odyssey Therapeutics completed an oversubscribed $218 million Series A round. The funds will be used to advance multiple programs from its pipeline and its discovery platform.
-
Recursion entered into a billion-dollar “transformational collaboration” with Roche to identify and develop up to 40 new medications for neuroscience and oncology.
-
Despite having 37 new mutations in the viral spike protein, there does not appear to be any deaths associated with Omicron, although it’s spreading rapidly in South Africa.